Tuis300601 • SHE
add
Shenzhen Kangtai Biological Prods Co Ltd
Vorige sluiting
¥18,29
Dagwisseling
¥18,16 - ¥18,85
Jaarwisseling
¥12,93 - ¥34,18
Markkapitalisasie
20,66 mjd CNY
Gemiddelde volume
18,60 m
P/V-verhouding
41,07
Dividend-opbrengs
2,05%
Primêre beurs
SHE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 816,14 m | 11,21% |
Bedryfskoste | 441,56 m | 6,14% |
Netto inkomste | 185,76 m | -0,46% |
Netto winsgrens | 22,76 | -10,50% |
Wins per aandeel | 0,16 | -2,13% |
EBITDA | 348,52 m | 22,34% |
Effektiewe belastingkoers | 6,09% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 310,71 m | -70,41% |
Totale bates | 14,52 mjd | -1,41% |
Totale aanspreeklikheid | 4,81 mjd | -6,59% |
Totale ekwiteit | 9,71 mjd | — |
Uitstaande aandele | 1,12 mjd | — |
Prys om te bespreek | 2,10 | — |
Opbrengs op bates | 5,17% | — |
Opbrengs op kapitaal | 6,38% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 185,76 m | -0,46% |
Kontant van bedrywe | 178,68 m | -37,64% |
Kontant van beleggings | -262,60 m | -774,60% |
Kontant van finansiering | -42,46 m | -25 008,80% |
Netto kontantverandering | -126,53 m | -149,37% |
Beskikbare kontantvloei | -1,95 mjd | -214,48% |
Meer oor
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
Gestig
08 Sep. 1992
Webwerf
Werknemers
1 902
